Experts are raising concerns about the risks associated with online platforms that allow betting on public health events, including vaccine mandates and drug trials. These platforms, such as Polymarket and Kalshi, enable users to wager on various health-related outcomes, from FDA approvals to CDC recommendations. Despite being largely unregulated, these prediction markets operate under federal commodities laws, avoiding state gambling regulations.
The lack of regulation raises concerns about potential insider trading and manipulation of drug trial outcomes. Critics argue that these platforms could incentivize trial participants to alter their behavior or drug companies to change trial timings. Additionally, the potential for insider information leaks poses a risk, as individuals with access to nonpublic information could profit from their insights.
The rise of these prediction markets highlights a gap in federal regulation, with no dedicated research centers or regulatory bodies addressing gambling-related issues. States like New Jersey are taking steps to restrict these markets, but broader federal action is still needed to address consumer protection and the potential for harm.
This summary was written with AI assistance from the original article and may leave out important context. The original reporting belongs to The Guardian · Health. Check the original, and official sources, before acting on any detail.